Dihydrophenanthridine

Dihydrophenanthridine

SCHEMBL2087461

c1ccc2c(c1)CNc1ccccc1-2

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.56
CA9 Q16790 2/20 0.56
ALOX15 P16050 1/20 0.56
HSD17B10 Q99714 1/20 0.56
GAA P10253 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
JAK2 O60674 1/20 0.50
HTR5A P47898 2/20 0.42
NOS2 P35228 1/20 0.41
HSD17B3 P37058 1/20 0.40
PLAU P00749 1/20 0.39
PARP1 P09874 2/20 0.38
PDPK1 O15530 1/20 0.38
PARP10 Q53GL7 1/20 0.38
PARP11 Q9NR21 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
TYRO3 Q06418 1/20 0.36
NTRK2 Q16620 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dihydrophenanthridine SCHEMBL29791568 1.00 CA12 (0.56) CA12CA9ALOX15HSD17B10GAA
SCHEMBL27425414 0.98 CA12 (0.54) CA12CA9ALOX15HSD17B10GAA
Dihydrophenanthridine SCHEMBL28195877 0.88 CA12 (0.50) CA12CA9ALOX15HSD17B10GAA
SCHEMBL19594919 0.85 PARP1 (0.49) CA12CA9ALOX15HSD17B10GAA
SCHEMBL21602736 0.83 ALOX15 (0.53) CA12CA9ALOX15HSD17B10GAA
SCHEMBL21665091 0.83 CA12 (0.48) CA12CA9ALOX15HSD17B10GAA
SCHEMBL11474110 0.83 CA12 (0.59) CA12CA9ALOX15HSD17B10GAA
SCHEMBL24591666 0.80 CA12 (0.46) CA12CA9ALOX15HSD17B10GAA
SCHEMBL20854469 0.80 METAP2 (0.53) CA12CA9ALOX15HSD17B10GAA
SCHEMBL17108096 0.80 JAK2 (0.54) CA12CA9ALOX15HSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119708022-A Boron-nitrogen-containing organic compound, application thereof and organic electroluminescent device 北京鼎材科技有限公司 2025-03-28 CN claimed
CN-119569758-A Boron-nitrogen-containing organic compound, application thereof and organic electroluminescent device 北京鼎材科技有限公司 2025-03-07 CN claimed
CN-109438349-A 6- (alpha-cyano imines) base phenanthridines class compound and its synthetic method 上海大学 2019-03-08 CN claimed
US-20140155591-A1 ARYLAMINE COMPOUND AND ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2014-06-05 US claimed
US-6903118-B1 Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides KLINGE PHARMA GMBH (DE) 2005-06-07 US claimed
JP-58074633-A None JP disclosed
US-12448370-B2 Heterocyclic compound and organic light-emitting device comprising same LG CHEM, LTD. (KR) 2025-10-21 US disclosed
CN-119708022-A Boron-nitrogen-containing organic compound, application thereof and organic electroluminescent device 北京鼎材科技有限公司 2025-03-28 CN disclosed
CN-119564683-A Combined synergistic pharmaceutical composition for resisting mycobacterial infection 首都医科大学附属北京胸科医院 2025-03-07 CN disclosed
CN-119569758-A Boron-nitrogen-containing organic compound, application thereof and organic electroluminescent device 北京鼎材科技有限公司 2025-03-07 CN disclosed
US-12215063-B2 Method for preparing deuterated compound LG CHEM, LTD. (KR) 2025-02-04 US disclosed
US-20240343750-A1 Metallocene Catalyst Compounds for Producing Polyolefins EXXONMOBIL TECHNOLOGY & ENGINEERING COMPANY (US) 2024-10-17 US disclosed
US-5512563-A TREATING DISEASES CAUSED BY EXCESS RENAL REABSORPTION OF WATER AMERICAN CYANAMID COMPANY (US) 1996-04-30 US disclosed
EP-0702004-A2 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives CIBA-GEIGY AG (CH) 1996-03-20 EP disclosed
EP-0655451-A1 Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-05-31 EP disclosed
EP-0640592-A1 N-acylated tricyclic azaheterorings useful as vasopressin antagonists AMERICAN CYANAMID COMPANY (US) 1995-03-01 EP disclosed
EP-0051284-B1 NOVEL THIAPROSTAGLANDIN E1 DERIVATIVES, PROCESS FOR PRODUCTION THEREOF, AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS TEIJIN LIMITED (JP) 1985-01-09 EP disclosed
US-4466980-A Thiaprostaglandin E1 derivatives, process for production thereof, and pharmaceutical use thereof TEIJIN LIMITED (JP) 1984-08-21 US disclosed
JP-S5874633-A PREPARATION OF CARBOXYLIC ACID TEIJIN LTD 1983-05-06 JP disclosed
EP-0051284-A1 Novel thiaprostaglandin E1 derivatives, process for production thereof, and pharmaceuticals containing these compounds TEIJIN LIMITED (JP) 1982-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12215063-B2 Method for preparing deuterated compound CYP2F1, CYP21A2, HSD11B2 CA12 319/4885CA9 270/4885ALOX15 1995/4885
US-20240343750-A1 Metallocene Catalyst Compounds for Producing Polyolefins MLX, TSNAX, TXLNA CA12 2779/4885CA9 4319/4885ALOX15 966/4885
US-12448370-B2 Heterocyclic compound and organic light-emitting device comprising same CCNT1, CCNA1, CYP1A1 CA12 3342/4885CA9 4006/4885ALOX15 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.